Pulmonary Arterial Hypertension Treatment Market Report

Global and Region Pulmonary Arterial Hypertension Treatment Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：204
  • REPORT CODE：GMM1010737
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.

    The report details the trend, potential and market size of Pulmonary Arterial Hypertension Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Pulmonary Arterial Hypertension Treatmentmarket, defines the market attractiveness level of Pulmonary Arterial Hypertension Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Pulmonary Arterial Hypertension Treatment industry, describes the types of Pulmonary Arterial Hypertension Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Pulmonary Arterial Hypertension Treatment market and the development prospects and opportunities of Pulmonary Arterial Hypertension Treatment industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Pulmonary Arterial Hypertension Treatment market in Chapter 13.

    By Player:

    • Eli Lilly and Company

    • United Therapeutic Corporation

    • Teva Pharmaceuticals Inc

    • Gilead Sciences, Inc

    • SteadyMed Ltd

    • GlaxoSmithKline plc

    • Bayer AG

    By Type:

    • Vasodilators

    • Phosphodiesterase 5 (PDE 5) Inhibitors

    • Endothelin Receptor Antagonists (ERA)

    • Soluble Guanylate Cyclase (SGC) Stimulator

    By End-User:

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Pulmonary Arterial Hypertension Treatment Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Pulmonary Arterial Hypertension Treatment Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Pulmonary Arterial Hypertension Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Pulmonary Arterial Hypertension Treatment Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Pulmonary Arterial Hypertension Treatment Market Analysis and Outlook to 2022

    • 7.1 Global Pulmonary Arterial Hypertension Treatment Consumption (2017-2022)

    • 7.2 United States Pulmonary Arterial Hypertension Treatment Consumption (2017-2022)

    • 7.3 Europe Pulmonary Arterial Hypertension Treatment Consumption (2017-2022)

    • 7.4 China Pulmonary Arterial Hypertension Treatment Consumption (2017-2022)

    • 7.5 Japan Pulmonary Arterial Hypertension Treatment Consumption (2017-2022)

    • 7.6 India Pulmonary Arterial Hypertension Treatment Consumption (2017-2022)

    • 7.7 South Korea Pulmonary Arterial Hypertension Treatment Consumption (2017-2022)

    8 Region and Country-wise Pulmonary Arterial Hypertension Treatment Market Analysis and Outlook to 2028

    • 8.1 Global Pulmonary Arterial Hypertension Treatment Consumption Forecast (2022-2028)

    • 8.2 United States Pulmonary Arterial Hypertension Treatment Consumption Forecast (2022-2028)

    • 8.3 Europe Pulmonary Arterial Hypertension Treatment Consumption Forecast (2022-2028)

    • 8.4 China Pulmonary Arterial Hypertension Treatment Consumption Forecast (2022-2028)

    • 8.5 Japan Pulmonary Arterial Hypertension Treatment Consumption Forecast (2022-2028)

    • 8.6 India Pulmonary Arterial Hypertension Treatment Consumption Forecast (2022-2028)

    • 8.7 South Korea Pulmonary Arterial Hypertension Treatment Consumption Forecast (2022-2028)

    9 Global Pulmonary Arterial Hypertension Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Pulmonary Arterial Hypertension Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Vasodilators Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Phosphodiesterase 5 (PDE 5) Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Endothelin Receptor Antagonists (ERA) Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Soluble Guanylate Cyclase (SGC) Stimulator Consumption and Growth Rate (2017-2022)

    • 9.2 Global Pulmonary Arterial Hypertension Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Retail Pharmacies Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Online Pharmacies Consumption and Growth Rate (2017-2022)

    10 Global Pulmonary Arterial Hypertension Treatment Market Outlook by Types and Applications to 2028

    • 10.1 Global Pulmonary Arterial Hypertension Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Vasodilators Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Phosphodiesterase 5 (PDE 5) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Endothelin Receptor Antagonists (ERA) Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Soluble Guanylate Cyclase (SGC) Stimulator Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Pulmonary Arterial Hypertension Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    11 Global Pulmonary Arterial Hypertension Treatment Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Pulmonary Arterial Hypertension Treatment Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Pulmonary Arterial Hypertension Treatment Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Pulmonary Arterial Hypertension Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Pulmonary Arterial Hypertension Treatment Market Competitive Analysis

    • 14.1 Eli Lilly and Company

      • 14.1.1 Eli Lilly and Company Company Details

      • 14.1.2 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product and Service

    • 14.2 United Therapeutic Corporation

      • 14.2.1 United Therapeutic Corporation Company Details

      • 14.2.2 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product and Service

    • 14.3 Teva Pharmaceuticals Inc

      • 14.3.1 Teva Pharmaceuticals Inc Company Details

      • 14.3.2 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product and Service

    • 14.4 Gilead Sciences, Inc

      • 14.4.1 Gilead Sciences, Inc Company Details

      • 14.4.2 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product and Service

    • 14.5 SteadyMed Ltd

      • 14.5.1 SteadyMed Ltd Company Details

      • 14.5.2 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product and Service

    • 14.6 GlaxoSmithKline plc

      • 14.6.1 GlaxoSmithKline plc Company Details

      • 14.6.2 GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Product and Service

    • 14.7 Bayer AG

      • 14.7.1 Bayer AG Company Details

      • 14.7.2 Bayer AG Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Bayer AG Pulmonary Arterial Hypertension Treatment Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Pulmonary Arterial Hypertension Treatment

    • Figure Pulmonary Arterial Hypertension Treatment Picture

    • Table Global Pulmonary Arterial Hypertension Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Pulmonary Arterial Hypertension Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Pulmonary Arterial Hypertension Treatment Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Pulmonary Arterial Hypertension Treatment Consumption by Country (2017-2022)

    • Figure United States Pulmonary Arterial Hypertension Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Pulmonary Arterial Hypertension Treatment Consumption and Growth Rate (2017-2022)

    • Figure China Pulmonary Arterial Hypertension Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Pulmonary Arterial Hypertension Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Pulmonary Arterial Hypertension Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Pulmonary Arterial Hypertension Treatment Consumption and Growth Rate (2017-2022)

    • Figure Global Pulmonary Arterial Hypertension Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Pulmonary Arterial Hypertension Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Pulmonary Arterial Hypertension Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Pulmonary Arterial Hypertension Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Pulmonary Arterial Hypertension Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Pulmonary Arterial Hypertension Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Pulmonary Arterial Hypertension Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Vasodilators Consumption and Growth Rate (2017-2022)

    • Figure Global Phosphodiesterase 5 (PDE 5) Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Endothelin Receptor Antagonists (ERA) Consumption and Growth Rate (2017-2022)

    • Figure Global Soluble Guanylate Cyclase (SGC) Stimulator Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Retail Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Online Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Vasodilators Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Phosphodiesterase 5 (PDE 5) Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Endothelin Receptor Antagonists (ERA) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Soluble Guanylate Cyclase (SGC) Stimulator Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Pulmonary Arterial Hypertension Treatment Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Pulmonary Arterial Hypertension Treatment Export by Region (Top 5 Countries) (2017-2028)

    • Table Eli Lilly and Company (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product and Service

    • Table United Therapeutic Corporation (Foundation Year, Company Profile and etc.)

    • Table United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product and Service

    • Table Teva Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product and Service

    • Table Gilead Sciences, Inc (Foundation Year, Company Profile and etc.)

    • Table Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product and Service

    • Table SteadyMed Ltd (Foundation Year, Company Profile and etc.)

    • Table SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product and Service

    • Table GlaxoSmithKline plc (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Product and Service

    • Table Bayer AG (Foundation Year, Company Profile and etc.)

    • Table Bayer AG Pulmonary Arterial Hypertension Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer AG Pulmonary Arterial Hypertension Treatment Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US